Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Lacerta Therapeutics on the deal. Lacerta Therapeutics announced its AAV capsid licensing and research collaboration agreement with Prevail Therapeutics. As a part of...
You must be a Standard 1 Year member to access this content.
Goodwin advised Gandeeva on the deal. Gandeeva announced its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Goldman Sachs & Co. LLC and the other underwriters on the deal. Omega Therapeutics, Inc. (Nasdaq: OMGA), a development-stage biotechnology company leveraging its OMEGA...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Omega Funds on the deal. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
You must be a Standard 1 Year member to access this content.
Goodwin Procter, Fried Frank and Appleby advised LumiraDx Limited on the deal, while Sidley Austin LLP acted for CA Healthcare Acquisition Corp. LumiraDx Limited announced its...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan...
You must be a Standard 1 Year member to access this content.
